- Home
- ERNA
as 12-18-2024 12:36pm EST
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 56.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.26 - $2.63 | Next Earning Date: | 11-12-2024 |
| Revenue: | $598,000 | Revenue Growth: | 1072.55% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Eterna Therapeutics Inc. News
ERNA Breaking Stock News: Dive into ERNA Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 days ago
Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models
GlobeNewswire
23 days ago
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
GlobeNewswire
a month ago
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
GlobeNewswire
2 months ago
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
TipRanks
2 months ago
Eterna, Factor announce license, collaboration agreement
GlobeNewswire
2 months ago
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
GlobeNewswire
7 months ago
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
GlobeNewswire
7 months ago
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
Compare ERNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ERNA Eterna Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.